Treat Oculocutaneous Albinism with Gene Therapy

Journal of Advances in Biology & Biotechnology, 16(3): 1-12, 2017. DOI:10.9734/JABB/2017/38504

12 Pages Posted: 17 Jul 2017 Last revised: 5 Jan 2018

See all articles by Martin Nelwan

Martin Nelwan

Nelwan Institution for Human Resource Development

Date Written: January 2, 2018

Abstract

Oculocutaneous albinism (OCA) is a group of hereditary recessive disorder recognized as a loss of pigmentation. OCA can derive from mutations in different genes that produce melanin. These mutations cause disturbances to get a standard melanin synthesis. There are 7 types of oculocutaneous albinism. These include OCA1, OCA2, OCA3, OCA4, OCA5, OCA6, and OCA7. To help OCA patients, it may include management of such as hats with brims and sunscreens. An effective therapy is unavailable for albinism at present. However, to fight OCA in the future, gene therapy can be used. Gene therapy can include use of such as retrovirus vectors, adenovirus vectors, and CRISPR/Cas9 system. Research results in animal models have shown remarkable advances. It means that the gene therapy will be helpful to treat people with albinism.

Keywords: albinism, albino, oculocutaneous albinism, gene therapy

Suggested Citation

Nelwan, Martin, Treat Oculocutaneous Albinism with Gene Therapy (January 2, 2018). Journal of Advances in Biology & Biotechnology, 16(3): 1-12, 2017. DOI:10.9734/JABB/2017/38504, Available at SSRN: https://ssrn.com/abstract=2561722 or http://dx.doi.org/10.2139/ssrn.2561722

Martin Nelwan (Contact Author)

Nelwan Institution for Human Resource Development ( email )

Jl. A. Yani No. 24
Palu, Sulawesi Tengah 94111
Indonesia

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
775
Abstract Views
4,477
rank
42,082
PlumX Metrics